Kura Oncology (KURA)
NASDAQ:KURA
Want to see KURA full AI Analyst Report?
Total Valuation
Kura Oncology has a market cap or net worth of $921.48M. The enterprise value is $834.76M.
Market Cap$921.48M
Enterprise Value$834.76M
Share Statistics
Kura Oncology has 88,774,370 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding88,774,370
Owned by Insiders2.37%
Owned by Institutions41.20%
Financial Efficiency
Kura Oncology’s return on equity (ROE) is -1.60 and return on invested capital (ROIC) is -48.76%.
Return on Equity (ROE)-1.60
Return on Assets (ROA)-0.38
Return on Invested Capital (ROIC)-48.76%
Return on Capital Employed (ROCE)-0.49
Revenue Per Employee259.55K
Profits Per Employee-1.07M
Employee Count260
Asset Turnover0.09
Inventory Turnover0.14
Valuation Ratios
The current PE Ratio of Kura Oncology is ―. Kura Oncology’s PEG ratio is -0.06.
PE Ratio―
PS Ratio13.50
PB Ratio5.23
Price to Fair Value5.23
Price to FCF-12.89
Price to Operating Cash Flow-12.07
PEG Ratio-0.06
Income Statement
In the last 12 months, Kura Oncology had revenue of 67.48M and earned -278.67M in profits. Earnings per share was -3.18.
Revenue67.48M
Gross Profit67.42M
Operating Income-303.63M
Pretax Income-278.37M
Net Income-278.67M
EBITDA-275.82M
Earnings Per Share (EPS)-3.18
Cash Flow
In the last 12 months, operating cash flow was -77.98M and capital expenditures -6.47M, giving a free cash flow of -84.46M billion.
Operating Cash Flow-77.98M
Free Cash Flow-84.46M
Free Cash Flow per Share-0.95
Dividends & Yields
Kura Oncology pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.47
52-Week Price Change83.10%
50-Day Moving Average9.45
200-Day Moving Average9.40
Relative Strength Index (RSI)65.22
Average Volume (3m)2.03M
Important Dates
Kura Oncology upcoming earnings date is Jul 30, 2026, After Close (Confirmed).
Last Earnings DateMay 12, 2026
Next Earnings DateJul 30, 2026
Ex-Dividend Date―
Financial Position
Kura Oncology as a current ratio of 6.06, with Debt / Equity ratio of 22.50%
Current Ratio6.06
Quick Ratio6.05
Debt to Market Cap0.01
Net Debt to EBITDA0.47
Interest Coverage Ratio-200.81
Taxes
In the past 12 months, Kura Oncology has paid 297.00K in taxes.
Income Tax297.00K
Effective Tax Rate>-0.01
Enterprise Valuation
Kura Oncology EV to EBITDA ratio is -2.84, with an EV/FCF ratio of -11.07.
EV to Sales11.59
EV to EBITDA-2.84
EV to Free Cash Flow-11.07
EV to Operating Cash Flow-12.21
Balance Sheet
Kura Oncology has $580.82M in cash and marketable securities with $24.27M in debt, giving a net cash position of $556.55M billion.
Cash & Marketable Securities$580.82M
Total Debt$24.27M
Net Cash$556.55M
Net Cash Per Share$6.27
Tangible Book Value Per Share$1.99
Margins
Gross margin is 94.66%, with operating margin of -449.94%, and net profit margin of -412.95%.
Gross Margin94.66%
Operating Margin-449.94%
Pretax Margin-412.51%
Net Profit Margin-412.95%
EBITDA Margin-408.74%
EBIT Margin-410.27%
Analyst Forecast
The average price target for Kura Oncology is $28.11, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$28.11
Price Target Upside190.40% Upside
Analyst ConsensusStrong Buy
Analyst Count10
Revenue Growth Forecast5.37%
EPS Growth Forecast-60.20%